Ginkgo bioworks stock prediction.

Based on Ginkgo Bioworks Holdings’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $80.7 million and a GAAP net loss of $204.97 million.27 Nov, 2023, 07:00 ET. Vivici has formed a partnership with Ginkgo to advance production of a sustainable and nutritious dairy protein, made via precision fermentation. Ginkgo will …Sep. 27, 2023, 07:01 AM. BOSTON, Sept. 27, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with Pfizer (NYSE: PFE) focused on the discovery of RNA-based drug ...First quarter 2023 Total revenue of $81 million, down from $168 million in the comparable prior year period, a decrease of 52% driven by the expected ramp down of K-12 testing in Ginkgo's ...Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) shares rose 17.5% to $4.10 in pre-market trading after the company said Q2 sales results were up year ... Also check this out: Walmart, Home Depot And 3 Stocks To Watch Heading Into Tuesday . Indic...

Added 21 new Cell Programs to the Foundry platform in Q2 2023, representing 62% growth over the prior year period. Ginkgo's Cell Engineering segment generated services revenue, which does not ...

Sep. 27, 2023, 07:01 AM. BOSTON, Sept. 27, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with Pfizer (NYSE: PFE) focused on the discovery of RNA-based drug ...

On that note, on August 29 Ginkgo Bioworks ( DNA 5.80%) announced that it is joining forces with Alphabet, Google's parent company, in a five-year strategic partnership to develop and use new ...Ginkgo has some real cred. 15B enterprise value over 64M in revenue for 2020 gives us a 234 price-to-sales ratio. If we use their 59M GAAP revenue it's 254. Moderna's is 24. They're not peers, and this is a higher growth industry, but it seems like a massive differential nonetheless for a stock right out of the gate.By John Blankenhorn, InvestorPlace Contributor Oct 7, 2023, 9:00 am EST. These biotech companies have invested in trials and tech to create a perfect launch for a breakout year. Gingko Bioworks ...Nov 21, 2023 · Ginkgo Bioworks Holdings Inc’s trailing 12-month revenue is $315.0 million with a -272.3% profit margin. Year-over-year quarterly sales growth most recently was -16.6%. Analysts expect adjusted earnings to reach $-0.442 per share for the current fiscal year.

Aug 22, 2023 · Ginkgo Bioworks. Wood has dipped her toes into the nascent eTVOL industry, but she's already ankle-deep in Ginkgo Bioworks' (DNA-2.52%) biofoundry platform. After the company bought millions more ...

By John Blankenhorn, InvestorPlace Contributor Oct 7, 2023, 9:00 am EST. These biotech companies have invested in trials and tech to create a perfect launch for a breakout year. Gingko Bioworks ...

Ginkgo Bioworks (DNA 8.53%) is a biotech unlike any other, and it's no surprise why it's consistently attracting the attention of bigwig portfolio managers like Cathie Wood.Ginkgo Bioworks Stock Price, News & Analysis (NYSE:DNA) $1.42 +0.14 (+10.89%) (As of 12/1/2023 ET) Compare Today's Range $1.28 $1.43 50-Day Range …Mar 30, 2022 · There are some variant perceptions on Ginkgo Bioworks Holdings, with the most bullish analyst valuing it at US$15.00 and the most bearish at US$6.00 per share. Note the wide gap in analyst price ... Evgenii Kovalev. Ginkgo Bioworks (NYSE:DNA) is still finding its feet as a public company, with the stock continuing to decline on the back of valuation concerns and declining Biosecurity revenue ...Sep 13, 2022 · Let's do a back-of-the-napkin calculation to determine whether this stock has a realistic chance of doubling in value in the next three years. At the moment, Ginkgo's market cap is around $4.5 ...

May 10, 2023 · First quarter 2023 Total revenue of $81 million, down from $168 million in the comparable prior year period, a decrease of 52% driven by the expected ramp down of K-12 testing in Ginkgo's ... BOSTON, Jan. 12, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today preliminary performance updates for the year ended December ...Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30 ...Under the terms of the merger agreement entered into on July 24, 2022, Zymergen stockholders received, for each share of Zymergen common stock, 0.9179 shares of Ginkgo Class A common stock ...Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) shares rose 17.5% to $4.10 in pre-market trading after the company said Q2 sales results were up year ... Also check this out: Walmart, Home Depot And 3 Stocks To Watch Heading Into Tuesday . Indic...

Ginkgo Bioworks (NYSE: DNA) sells something very original: the large-scale design and production of organisms. And thanks to its innovations, the company has increased revenue almost 800% over the ...

Ginkgo Bioworks (NYSE: DNA), ... Forward-looking statements are predictions, ... (NASDAQ:AVGO) stock skyrocketed 79% YTD on the back of the AI wave.DNA Stock. USD 1.57 0.00 0.00%. Ginkgo Bioworks Holdings stock price prediction is an act of determining the future value of Ginkgo Bioworks shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Ginkgo Bioworks' future price could yield a ...Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. [Read more] In 2022, DNA's revenue was $477.71 million, an increase of 52.21% compared to the previous year's $313.84 million. Losses were -$2.10 billion, 15.0% more than in 2021.May 4, 2023 · In the past year, Ginkgo's growth rate has been falling. And for the last three months of 2022, its revenue fell by 34% year over year as a result of what management said was an "expected ... 733.3157. 57.0849. -288.9. -6,916. Get the detailed quarterly/annual income statement for Ginkgo Bioworks Holdings, Inc. (DNA). Find out the revenue, expenses and profit or loss over the last ...BOSTON, March 1, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2022.The current Ginkgo Bioworks Holdings [ DNA] share price is $1.43. The Score for DNA is 19, which is 62% below its historic median score of 50, and infers higher risk than normal. DNA is currently trading in the 10-20% percentile range relative to its historical Stock Score levels.In about an hour following the publication of Scorpion’s 175-page report, Ginkgo’s stock price dropped at least 20%, down to about $9.50 a share.In the context of stocks in the large market cap category, GINKGO BIOWORKS HOLDINGS INC's number of analysts covering the stock is higher than 432.89% of them.As of June 2, 2023, the average one-year price target for Ginkgo Bioworks Holdings Inc - is 4.55. The forecasts range from a low of 1.77 to a high of $12.60. The average price target represents an ...

According to CBS News, Harry Dent’s predictions in his books have never been right. His most accurate prediction was from his 1993 book; he predicted that the stock market would rise substantially, but he was a year early with his predictio...

Ginkgo Bioworks Holdings' estimated fair value is US$1.81 based on 2 Stage Free Cash Flow to Equity. Current share price of US$1.33 suggests Ginkgo Bioworks Holdings is potentially 26% undervalued ...

Aug 14, 2023 · 1 DNA stock price increased by 6.86% over the past day and the current price is below all major EMA’s. 2 Ginkgo Bioworks Holdings Inc. ( NYSE: DNA) stock’s 52-week price range is around $1.12 – $2.55. Ginkgo Bioworks Holdings Inc. reported Q2 revenue is down 44% Y-o-Y, mainly due to a fall in Biosecurity revenue. Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31 ...As the stock market is expected to remain under tremendous pressure in the near term, it could be wise to avoid fundamentally weak and overvalued Cathie Wood stocks Ginkgo Bioworks Holdings, Inc. (DNA), UiPath Inc. (PATH), Rocket Lab USA, Inc. (RKLB), and Verve Therapeutics, Inc. (VERV).Ginkgo Bioworks Holdings, Inc. ()DNA develops …Ginkgo Bioworks Reports Fourth Quarter and Full Year 2021 Financial Results. $314 million of Total revenue in 2021, representing an increase of 309% over 2020. 31 new Cell Programs added in 2021 ...Ginkgo Bioworks (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, and Google Cloud today announced a five-year strategic cloud and AI partnership ...Find Salaries by Job Title at Ginkgo BioWorks. 25 Salaries (for 18 job titles) • Updated Oct 29, 2023. How much do Ginkgo BioWorks employees make? Glassdoor provides our best prediction for total pay in today's job market, along with other types of pay like cash bonuses, stock bonuses, profit sharing, sales commissions, and tips.Jul 25, 2023 · Among her various holdings in this high-growth area, Prime Medicine (PRME 11.02%) and Ginkgo Bioworks Holdings (DNA 10.85%) stand out as two of the most promising companies within her portfolios ... Ginkgo Bioworks. 15 Nov, 2022, 16:17 ET. BOSTON, Nov. 15, 2022 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"),which is building the leading platform for cell programing and ..."Ginkgo is committed to harnessing the power of programmable biology to enable sustainable food production and food security worldwide," said Jason Kelly, CEO and co-founder of Ginkgo Bioworks. "We look forward to partnering with Bayer and other innovative companies, and to bringing more applications on to Ginkgo's expanded …Sep 21, 2021 · So what. Initiating coverage on Ginkgo Bioworks, Sriharsha Pappu, an HSBC analyst, assigned a buy rating on the stock and a $14 price target. According to TheFly.com, Pappu believes that the ...

Get the latest Ginkgo Bioworks Holdings Inc (DNA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction. See More Share. DNA Stock Quotes API ...Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results. DNA | March 1, 2023. $478 million of total revenue in 2022, representing an increase of 52% over 2021 and toward the high end of guidance. 59 new Cell Programs added in 2022, representing 90% growth over 2021 and toward the high end of guidance.Instagram:https://instagram. dollar tree inc.2009 pennysrun tickerbest day trading apps Ginkgo Bioworks, a synthetic biology company now valued at around $15 billion, begins trading on the New York Stock Exchange today. Ginkgo’s market debut is one of the largest in biotech history. buy otc stocksbest stock charts website Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and ... best crowdfunding sites real estate As a member of the SPAC class of 2021, Ginkgo Bioworks ( NYSE: DNA) stock has seen its fair share of pummeling over the last few years. From an all-time high at ~$16 to the stock's current price ...Get the latest Ginkgo Bioworks Holdings Inc (DNA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …